Pfizer posts transcript of Q2 2026 earnings call

PFE•2026-08-05

Product commentary

Management highlighted Padcev momentum, noting Q2 growth above 20% with la/mUC new patient share above 60%. Growth is expected to moderate as penetration rises.

Cost savings and outlook

Expanded cost programs targeted about $2.5 billion in net savings in 2027-2029. Total net savings are expected to be about $9.7 billion through 2029.

Earnings call highlights

Pfizer’s Q2 2026 earnings call drew CEO Albert Bourla, CFO David Denton, incoming interim CFO Cecile Guegan and Chief Oncology Officer Chris Boshoff.

Revenue guidance midpoint was lifted by $500 million to a $60.5 billion-$62.5 billion range.
The COVID-19 revenue view was cut to about $4 billion.
Q2 revenue totaled $15 billion.
Adjusted diluted EPS was $0.77.
Adjusted diluted EPS guidance was held at $2.80-$3 despite a $0.10 Innovent charge.